Improving modeling and simulation of complex targets
Drug discovery through simulation and modeling requires unprecedented computational capacities exceeding one petaflop, or more than one million billion operations per second. For Qubits Pharmaceuticals, the future of molecular modeling and simulation in drug discovery should lie in the hybrid use of classical supercomputers and quantum computers, with quantum computers serving as gas pedals for certain key calculations alongside GPU supercomputers. To explore this new area of research, Qubit has chosen NVIDIA QODA, a hybrid quantum-classical computing platform. It enables the seamless integration of quantum computing with GPU-accelerated supercomputing, and is compatible with all quantum resources, including physical QPUs and emulation with cuQuantum. QPUs, or quantum processing units, could accelerate key software kernels for molecular modeling. The NVIDIA cuQuantum SDK, meanwhile, allows Qubit developers to simulate quantum circuits and thus design algorithms ready to run on future quantum computers. Qubits' new platform is accelerated by 200 GPUs (next-generation graphics cards) including NVIDIA DGX A100 systems, offering unparalleled power for AI simulation and computation, according to the company. The combination of NVIDIA's accelerated computing platform and Qubit's Atlas software aims to cut the time required to screen, select and optimize a drug candidate of interest by more than a factor of 2 and the investment required by more than a factor of 10. Initially, this new platform aims to develop 10 internal research programs in the fields of oncology, inflammatory diseases and antivirals. The first drug candidates should be tested by pharmaceutical companies as early as 2023. Robert Marino, CEO of Qubit Pharmaceuticals states:"We are extremely proud two years after Qubit's inception to have earned the trust of a global leader like NVIDIA. By combining NVIDIA's computational power with Qubit's simulation and molecular modeling capabilities, we are confident in our ability to dramatically reduce drug development time and cut the cost of pre-clinical development by a factor of ten. This unique collaboration is also groundbreaking in the field of quantum physics and should enable us to develop the first algorithms in this field applied to drug discovery."Translated from Qubit Pharmaceuticals s'appuie sur NVIDIA et l'informatique quantique hybride pour accélérer la découverte de médicaments
Our articles will then appear first in Google Top Stories.
